文献速递肝病

血清纤维化检测指导MAFLD患者预后

Serum Fibrosis Tests Guide Prognosis in Metabolic Dysfunction-Associated Fatty Liver Disease Patients Referred From Primary Care.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-10-06

该研究分析了初级保健转诊的MAFLD患者,评估Hepascore、APRI、FIB-4和NAFLD纤维化评分对肝脏相关结局的预测准确性。结果显示Hepascore和FIB-4的曲线下面积最高,Hepascore特异性最高且决策曲线分析净获益最大,可作为筛查工具。

要点

  • Hepascore和FIB-4对肝脏相关死亡、失代偿和肝癌的预测AUC较高。
  • Hepascore截断值0.60时敏感性和阴性预测值均>90%。
  • Hepascore特异性最高,决策曲线分析净获益最大。

核心结论

  • 血清无创检测可准确分层MAFLD患者肝脏相关结局风险,可作为初级保健转诊患者的筛查工具。

研究设计与样本

  • 研究纳入初级保健转诊至Sir Charles Gairdner医院(队列1,n=626)或西澳大利亚三级中心(队列2,n=246)的MAFLD患者。
  • 基线时进行Hepascore、AST/血小板比值指数、FIB-4和NAFLD纤维化评分检测,评估其预测肝脏相关死亡、失代偿和肝细胞癌的准确性。

主要发现

  • 队列1中位随访5.0年(范围0.1-13.0年),队列2中位随访3.8年(范围0.1-10.0年)。
  • 两个队列中Hepascore预测肝脏相关死亡的AUC为0.90-0.95,FIB-4为0.83-0.94;预测失代偿的AUC分别为0.86-0.91和0.86-0.87;预测肝细胞癌的AUC分别为0.75-0.90和0.67-0.85。
  • 队列1中Hepascore(截断值0.60)、FIB-4(截断值1.30)和NAFLD纤维化评分(截断值-1.455)对所有结局的敏感性和阴性预测值均>90%;队列2中预测肝脏相关死亡的敏感性和阴性预测值>90%。
  • Hepascore特异性最高,将最大比例患者归类为低风险,决策曲线分析显示净获益最大。

关键数值与推荐

  • Hepascore截断值0.60时,队列1中所有结局的敏感性和阴性预测值>90%。
  • FIB-4截断值1.30时,队列1中所有结局的敏感性和阴性预测值>90%。
  • NAFLD纤维化评分截断值-1.455时,队列1中所有结局的敏感性和阴性预测值>90%。

临床怎么用

  • 对于初级保健转诊的MAFLD患者,可使用Hepascore或FIB-4等血清无创检测进行风险分层,以识别需要专科进一步评估的高风险患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Metabolic dysfunction-associated fatty liver disease (MAFLD) is managed predominately in primary care, however, there is uncertainty regarding how to best identify patients for specialist referral. We examined the accuracy of noninvasive tests as screening tools for the prediction of outcomes in MAFLD patients referred from primary care. METHODS: Patients with MAFLD referred by primary care for specialist review to Sir Charles Gairdner Hospital (cohort 1, n = 626) or tertiary centers within Western Australia (cohort 2, n = 246) were examined. Hepascore, aspartate aminotransferase to platelet ratio, Fibrosis-4 (FIB-4), and nonalcoholic fatty liver disease fibrosis score performed at baseline were examined for their accuracy in predicting liver-related death (LRD), decompensation, and hepatocellular carcinoma. Outcomes were collected from hospital records and data linkage. RESULTS: The median follow-up period was 5.0 years (range, 0.1-13.0 y) and 3.8 years (range, 0.1-10.0 y) in cohorts 1 and 2, respectively. In both cohorts, Hepascore and FIB-4 had the highest area under the curve for the prediction of LRD (0.90-0.95 and 0.83-0.94, respectively), decompensation (0.86-0.91 and 0.86-0.87, respectively), and hepatocellular carcinoma (0.75-0.90 and 0.67-0.85, respectively). The sensitivity and negative predictive values were high (>90%) for Hepascore (cut-off value, 0.60), FIB-4 (cut-off value, 1.30), and nonalcoholic fatty liver disease fibrosis score (cut-off value, -1.455) for all outcomes in cohort 1, and for predicting LRD in cohort 2. Hepascore had the highest specificity, classified the greatest proportion of patients as low risk, and was favored by decision curve analysis as providing the greatest net benefit. CONCLUSIONS: Serum noninvasive tests accurately stratify risk of liver-related outcomes in MAFLD patients and can be used as a screening tool for patients referred for specialist review by primary care.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Wang Z, Bertot LC, Jeffrey GP, et al. Serum Fibrosis Tests Guide Prognosis in Metabolic Dysfunction-Associated Fatty Liver Disease Patients Referred From Primary Care. Clin Gastroenterol Hepatol. 2021. PMID: 34624564. doi:10.1016/j.cgh.2021.09.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。